PlainRecalls
FDA Drug Low Class III Terminated

buPROPion HCl Extended-Release Tablets, USP (SR), 100 mg, 60 count bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788 --- NDC 69097-877-03

Reported: April 11, 2018 Initiated: March 15, 2018 #D-0618-2018

Product Description

buPROPion HCl Extended-Release Tablets, USP (SR), 100 mg, 60 count bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788 --- NDC 69097-877-03

Reason for Recall

Failed Dissolution Specifications; during stability testing

Details

Units Affected
N/A
Distribution
Nationwide
Location
Hauppauge, NY

Frequently Asked Questions

What product was recalled?
buPROPion HCl Extended-Release Tablets, USP (SR), 100 mg, 60 count bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788 --- NDC 69097-877-03. Recalled by InvaGen Pharmaceuticals, Inc.. Units affected: N/A.
Why was this product recalled?
Failed Dissolution Specifications; during stability testing
Which agency issued this recall?
This recall was issued by the FDA Drug on April 11, 2018. Severity: Low. Recall number: D-0618-2018.